GSK’s ViiV Sues Hetero to Block Copies of Triumeq HIV Drug

GlaxoSmithKline Plc’s ViiV Healthcare Co. alleges in a federal lawsuit that Hetero Labs Ltd.’s proposed copy of Triumeq infringes a patent for the blockbuster HIV treatment.

ViiV and Shionogi & Co. allege that Hetero’s generic version infringes US Patent No. 9,242,986, which Shionogi licenses exclusively to co-plaintiff ViiV Healthcare UK (No. 3) Ltd., according to a complaint filed Monday in the US District Court for the District of Delaware. The suit lands one month after another case, pending in the same federal court, involving the same parties and the same patent, but alleging infringement by the related blockbuster ...